PCM
SCPH

Prelude Capital Management’s scPharmaceuticals SCPH Stock Holding History

Prelude Capital Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-400
Closed -$3K – 1888
2020
Q3 		$3K Buy
+400
New +$3.13K ﹤0.01% 1636
2019
Q4 		– Sell
-1,300
Closed -$8K – 2203
2019
Q3 		$8K Buy
+1,300
New +$7.33K ﹤0.01% 1517
2018
Q2 		– Sell
-24,330
Closed -$302K – 1908
2018
Q1 		$302K Buy
+24,330
New +$327K 0.02% 585

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Prelude Capital Management's SCPH Position: Q4 2020 in Review

Prelude Capital Management sold out of scPharmaceuticals (SCPH) in Q4 2020, closing a stake of 400 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in SCPH in Q1 2018 and held it in 3 quarters. The position peaked at $302K in Q1 2018. 47 funds tracked by Wall St. Rank hold SCPH as of Q4 2020.

  • Prelude Capital Management reported no remaining scPharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 400 scPharmaceuticals shares in Q4 2020, an estimated $3K.
  • Prelude Capital Management first reported a position in scPharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Prelude Capital Management's scPharmaceuticals position peaked at $302K in Q1 2018.
  • 47 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.